

Martin Fassnacht

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11689700/martin-fassnacht-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

12,394
citations

56
h-index

110
g-index

181
ext. papers

15,165
ext. citations

7.5
avg, IF

6.06
L-index

#	Paper	IF	Citations
166	Adrenal Functional Imaging.. <i>Presse Medicale</i> , 2022 , 51, 104114	2.2	0
165	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study.. <i>Annals of Internal Medicine</i> , 2022 ,	8	2
164	The role of molecular profiling in adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2021 ,	3.4	1
163	Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	1
162	Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses. <i>European Journal of Endocrinology</i> , 2021 , 186, 183-193	6.5	3
161	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. <i>European Journal of Endocrinology</i> , 2021 , 186, 25-36	6.5	4
160	Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?. <i>Cancers</i> , 2021 , 13,	6.6	1
159	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	5
158	Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. <i>Clinical Chemistry</i> , 2021 , 67, 998-1007	5.5	2
157	Predictive Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. <i>Hormone and Metabolic Research</i> , 2021 , 53, 24-31	3.1	1
156	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , 2021 , 110, 50-61	3.7	7
155	PKA C β subunit mutation triggers caspase-dependent RII α subunit degradation via Ser phosphorylation. <i>Science Advances</i> , 2021 , 7,	14.3	1
154	Novel CYP11B-ligand [I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1	8.8	1
153	Case Report: Consecutive Adrenal Cushing β Syndrome and Cushing β Disease in a Patient With Somatic , , and Mutations. <i>Frontiers in Endocrinology</i> , 2021 , 12, 731579	5.7	1
152	Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. <i>British Journal of Cancer</i> , 2021 , 125, 1233-1238	8.7	1
151	Management of Patients With Glucocorticoid-Related Diseases and COVID-19. <i>Frontiers in Endocrinology</i> , 2021 , 12, 705214	5.7	1
150	Identifying New Potential Biomarkers in Adrenocortical Tumors Based on mRNA Expression Data Using Machine Learning. <i>Cancers</i> , 2021 , 13,	6.6	2

149	Simulation-Based Interpretation of Therapeutically Monitored Cabozantinib Plasma Concentration in Advanced Adrenocortical Carcinoma with Hemodialysis. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 706-711 ^{3,2}		
148	Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. <i>European Journal of Endocrinology</i> , 2021 , 184, 167-178	6.5	3
147	Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 795116	5.7	0
146	Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2020 , 11, 597878	5.7	7
145	Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2020 , 11, 219	5.7	10
144	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma 2020 , 8,		25
143	Next-generation therapies for adrenocortical carcinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020 , 34, 101434	6.5	26
142	Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. <i>Cell Death and Disease</i> , 2020 , 11, 192	9.8	11
141	Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. <i>Cancers</i> , 2020 , 12,	6.6	8
140	Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer. <i>Cancers</i> , 2020 , 12,	6.6	5
139	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. <i>Cancers</i> , 2020 , 12,	6.6	14
138	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	12
137	Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma. <i>Endocrine Connections</i> , 2020 , 9, 705-714	3.5	6
136	Nebennierenkarzinom. <i>Springer Reference Medizin</i> , 2020 , 1-6	0	
135	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. <i>Investigational New Drugs</i> , 2020 , 38, 1421-1429	4.3	19
134	Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	27
133	Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	17
132	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 773-781	18.1	56

131	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	12
130	Prognostic Relevance of Steroid Sulfation in Adrenocortical Carcinoma Revealed by Molecular Phenotyping Using High-Resolution Mass Spectrometry Imaging. <i>Clinical Chemistry</i> , 2019 , 65, 1276-1286	5.5	8
129	Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing Syndrome. <i>Endocrinology</i> , 2019 , 160, 447-459	4.8	16
128	Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2535-2546	5.6	19
127	A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring. <i>Analytical and Bioanalytical Chemistry</i> , 2019 , 411, 3951-3962	4.4	7
126	Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2019 , 10, 487	5.7	4
125	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. <i>JAMA Oncology</i> , 2019 , 5, 1440-1447	13.4	31
124	Driver mutations in USP8 wild-type Cushing β disease. <i>Neuro-Oncology</i> , 2019 , 21, 1273-1283	1	32
123	Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 22269-22274	11.5	49
122	The New Genetic Landscape of Cushing β Disease: Deubiquitinases in the Spotlight. <i>Cancers</i> , 2019 , 11,	6.6	15
121	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 312-318	5.6	59
120	Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. <i>Annals of Surgical Oncology</i> , 2019 , 26, 531-538	3.1	12
119	Advanced Adrenocortical Carcinoma - What to do when First-Line Therapy Fails?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019 , 127, 109-116	2.3	22
118	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019 , 127, 578-584	2.3	8
117	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1686-1695	5.6	66
116	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2018 , 71, 317-325	8.5	46
115	High-Resolution Tissue Mass Spectrometry Imaging Reveals a Refined Functional Anatomy of the Human Adult Adrenal Gland. <i>Endocrinology</i> , 2018 , 159, 1511-1524	4.8	23
114	European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. <i>European Journal of Endocrinology</i> , 2018 , 179, G1-G46	6.5	303

113	Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives. <i>Endocrine</i> , 2018 , 62, 506-516	4	7
112	Medikamentöse Therapie des Nebennierenkarzinoms. <i>Onkologe</i> , 2018 , 24, 118-123	0.1	1
111	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated -Methylated Catecholamine Metabolites. <i>Clinical Chemistry</i> , 2018 , 64, 1646-1656	5.5	67
110	Surviving ectopic Cushing β syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing β disease during long-term follow-up. <i>European Journal of Endocrinology</i> , 2018 , 179, 109-116	6.5	15
109	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. <i>European Journal of Endocrinology</i> , 2018 , 178, 181-188	6.5	10
108	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 4511-4523	5.6	55
107	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017 , 31, 181-193	24.3	350
106	Dosage-dependent regulation of expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. <i>Science Signaling</i> , 2017 , 10,	8.8	24
105	Topoisomerase 2 β and thymidylate synthase expression in adrenocortical cancer. <i>Endocrine-Related Cancer</i> , 2017 , 24, 319-327	5.7	18
104	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1358-1365	5.6	75
103	Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. <i>Clinical Nuclear Medicine</i> , 2017 , 42, e29-e34	1.7	35
102	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing β syndrome. <i>European Journal of Endocrinology</i> , 2017 , 177, 227-237	6.5	13
101	Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. <i>Scientific Reports</i> , 2017 , 7, 49	4.9	15
100	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 4323-4332	5.6	50
99	Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study. <i>BMC Cancer</i> , 2017 , 17, 522	4.8	20
98	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3491-3498	5.6	24
97	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. <i>Oncotarget</i> , 2017 , 8, 9323-9338	3.3	20
96	Laparoskopische Adrenalektomie 2017 , 187-195		

95	DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 923-932	5.6	35
94	Adrenocortical Carcinoma 2016 , 1862-1870.e3		
93	Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. <i>Endocrine-Related Cancer</i> , 2016 , 23, 825-37	5.7	13
92	DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2016 , 175, R65-80	6.5	60
91	Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. <i>Hormones and Cancer</i> , 2016 , 7, 345-355	5	11
90	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 3526-38	5.6	46
89	Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016 , 7, 211-8		13
88	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2016 , 174, 343-53	6.5	14
87	Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. <i>European Journal of Endocrinology</i> , 2016 , 174, 363-72	6.5	59
86	Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3383-8	15.9	40
85	Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas. <i>PLoS ONE</i> , 2016 , 11, e0169009	3.7	7
84	Inhibition of Cholesterol Esterification in the Adrenal Gland by ATR101/PD132301-2, A Promising Case of Drug Repurposing. <i>Endocrinology</i> , 2016 , 157, 1719-21	4.8	5
83	Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. <i>European Journal of Endocrinology</i> , 2016 , 175, G1-G34	6.5	715
82	Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography. <i>Endocrine</i> , 2016 , 53, 791-800	4	4
81	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016 , 29, 723-736	24.3	324
80	MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2016 , 175, R51-64	6.5	106
79	FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria. <i>EMBO Reports</i> , 2016 , 17, 1264-80	6.5	86
78	Expression of LIN28 and its regulatory microRNAs in adult adrenocortical cancer. <i>Clinical Endocrinology</i> , 2015 , 82, 481-8	3.4	20

77	Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. <i>European Journal of Endocrinology</i> , 2015 , 172, 415-22	6.5	35
76	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. <i>Lancet Oncology</i> , 2015 , 16, 426-35	21.7	209
75	The New Molecular Landscape of Cushing β Disease. <i>Trends in Endocrinology and Metabolism</i> , 2015 , 26, 573-583	8.8	23
74	Decoding the genetic basis of Cushing β disease: USP8 in the spotlight. <i>European Journal of Endocrinology</i> , 2015 , 173, M73-83	6.5	32
73	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. <i>Endocrine-Related Cancer</i> , 2015 , 22, 531-43	5.7	24
72	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. <i>Endocrinology</i> , 2015 , 156, 3895-908	4.8	115
71	Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors. <i>Hormones and Cancer</i> , 2015 , 6, 225-36	5	5
70	A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma. <i>BMC Surgery</i> , 2015 , 15, 93	2.3	3
69	Mutations in the deubiquitinase gene USP8 cause Cushing β disease. <i>Nature Genetics</i> , 2015 , 47, 31-8	36.3	339
68	Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E776-82	5.6	39
67	Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 4604-11	5.6	11
66	Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 841-9	5.6	199
65	High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 407-16	5.6	210
64	Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. <i>European Urology</i> , 2014 , 65, 832-8	10.2	87
63	Integrated genomic characterization of adrenocortical carcinoma. <i>Nature Genetics</i> , 2014 , 46, 607-12	36.3	423
62	Constitutive activation of PKA catalytic subunit in adrenal Cushing β syndrome. <i>New England Journal of Medicine</i> , 2014 , 370, 1019-28	59.2	284
61	CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma. <i>PLoS ONE</i> , 2014 , 9, e105855	3.7	33
60	Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing β syndrome: a European multicentric study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E2093-100	5.6	67

59	PKA catalytic subunit mutations in adrenocortical Cushing β adenoma impair association with the regulatory subunit. <i>Nature Communications</i> , 2014 , 5, 5680	17.4	49
58	EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. <i>European Journal of Endocrinology</i> , 2014 , 171, R1-R11	6.5	32
57	Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2014 , 170, 707-17	6.5	7
56	Nebennierenkarzinom 2014 , 1-3		
55	Update in adrenocortical carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4551-64	5.6	280
54	Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5 β -reductase, explaining the need for personalized glucocorticoid and androgen replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 161-71	5.6	104
53	Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1508-18	5.6	35
52	[123I]Iodometomidate imaging in adrenocortical carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 2755-64	5.6	33
51	The role of surgery in the management of recurrent adrenocortical carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 181-91	5.6	110
50	Single nucleotide polymorphism array profiling of adrenocortical tumors--evidence for an adenoma carcinoma sequence?. <i>PLoS ONE</i> , 2013 , 8, e73959	3.7	47
49	Clinical impact of TP53 alterations in adrenocortical carcinomas. <i>Langenbeck's Archives of Surgery</i> , 2012 , 397, 209-16	3.4	33
48	Single nucleotide polymorphism microarray analysis in cortisol-secreting adrenocortical adenomas identifies new candidate genes and pathways. <i>Neoplasia</i> , 2012 , 14, 206-18	6.4	28
47	[131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 914-22	5.6	56
46	Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 3452-61	12.9	54
45	Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E2251-60	5.6	33
44	Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3495-503	5.6	115
43	TP53 germline mutations in adult patients with adrenocortical carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E476-85	5.6	80
42	Combination chemotherapy in advanced adrenocortical carcinoma. <i>New England Journal of Medicine</i> , 2012 , 366, 2189-97	59.2	510

41	Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. <i>Annals of Surgery</i> , 2012 , 255, 363-9	7.8	118
40	Adrenocortical carcinoma: a clinician's update. <i>Nature Reviews Endocrinology</i> , 2011 , 7, 323-35	15.2	265
39	Sunitinib Inhibits Cell Proliferation and Alters Steroidogenesis by Down-Regulation of HSD3B2 in Adrenocortical Carcinoma Cells. <i>Frontiers in Endocrinology</i> , 2011 , 2, 27	5.7	21
38	Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2011 , 75, 585-91	3.4	87
37	Contemporary management of adrenocortical carcinoma. <i>European Urology</i> , 2011 , 60, 1055-65	10.2	77
36	Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. <i>Annals of Thoracic Surgery</i> , 2011 , 92, 1965-70	2.7	35
35	Plasma concentrations of o,p β DDD, o,p β DDA, and o,p β DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1844-51	5.6	125
34	Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3775-84	5.6	293
33	β -catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. <i>Clinical Cancer Research</i> , 2011 , 17, 328-36	12.9	110
32	Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. <i>Clinical Endocrinology</i> , 2010 , 72, 305-11	3.4	26
31	What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?. <i>Clinical Endocrinology</i> , 2010 , 73, 561-5	3.4	36
30	Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2010 , 162, 349-56	6.5	97
29	Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. <i>Journal of Clinical Oncology</i> , 2010 , 28, e401-2; author reply e403	2.2	84
28	Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. <i>European Journal of Endocrinology</i> , 2010 , 162, 597-602	6.5	209
27	Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 4925-32	5.6	118
26	Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. <i>Modern Pathology</i> , 2010 , 23, 1596-604	9.8	43
25	High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, E161-71	5.6	156
24	Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. <i>European Urology</i> , 2010 , 58, 609-15	10.2	207

23	Deficits in the management of patients with adrenocortical carcinoma in Germany. <i>Deutsches A&#x0308;rzteblatt International</i> , 2010 , 107, 885-91	2.5	34
22	Adrenocortical Carcinoma 2010 , 1951-1958		1
21	Nebennierenrindenzkarzinom 2010 , 225-230		
20	Frequent incidental discovery of pheochromocytoma: data from a German cohort of 201 pheochromocytoma. <i>European Journal of Endocrinology</i> , 2009 , 161, 355-61	6.5	132
19	Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. <i>Endocrine-Related Cancer</i> , 2009 , 16, 919-28	5.7	64
18	Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. <i>Endocrine-Related Cancer</i> , 2009 , 16, 907-18	5.7	48
17	New targets and therapeutic approaches for endocrine malignancies. <i>Pharmacology & Therapeutics</i> , 2009 , 123, 117-41	13.9	90
16	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. <i>Cancer</i> , 2009 , 115, 243-50	6.4	446
15	Radiotherapy in adrenocortical carcinoma. <i>Cancer</i> , 2009 , 115, 2816-23	6.4	128
14	Reply to Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. <i>Cancer</i> , 2009 , 115, 5848-5848	6.4	5
13	Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. <i>Journal of Pathology</i> , 2009 , 218, 232-40	9.4	11
12	Clinical management of adrenocortical carcinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009 , 23, 273-89	6.5	200
11	Epidemiology of Adrenocortical Carcinoma 2009 , 23-29		1
10	Clinical Presentation and Initial Diagnosis 2009 , 31-47		
9	Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2057-62	5.6	122
8	Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. <i>Endocrinology</i> , 2008 , 149, 1314-22	4.8	44
7	[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2358-65	5.6	72
6	Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3912-22	5.6	201

5	Adjuvant mitotane treatment for adrenocortical carcinoma. <i>New England Journal of Medicine</i> , 2007 , 356, 2372-80	59.2	568
4	Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4501-4	5.6	181
3	Clinical review: Adrenocortical carcinoma: clinical update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2027-37	5.6	561
2	Mitotane for adrenocortical carcinoma treatment. <i>Current Opinion in Investigational Drugs</i> , 2005 , 6, 386-94		87
1	Management of adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2004 , 60, 273-87	3.4	160